MedTrace Logo

Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia

NCT00608179 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-12-11

No results posted yet for this study

Summary

This study will look at two FDA approved medications that improve how the pancreas works in patients with Type 2 Diabetes. In order to understand how these medications work in patients with diabetes we must first measure the normal response in healthy volunteers without diabetes. We will be looking at the body's normal physiological response to low blood sugar and whether this will be modified by these medicationsThe hypothesis would be that glimepiride induced insulin secretion will be inhibited by hypoglycemia.

Conditions

Interventions

DRUG

Glimepiride

Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.

DRUG

glyburide

Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.

OTHER

glucose clamp

Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes

OTHER

glucose clamp

hypoglycemic glucose clamp procedure -120 minutes

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Stephen N. Davis, MD · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2004-09-30
Completion
2010-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608179 on ClinicalTrials.gov